Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK, gives an overview of the CLL pilot run by Genomics England to test the robustness of the sample pathway for liquid cancers. Dr Schuh outlines the project, which has recruited over 300 chronic lymphocytic leukemia (CLL) patients from clinical trials. The aim is to identify new predictors of response to treatment, understanding the significance of non-coding regions and changes in the germline that might be important for drug metabolism. She further explains how more patients need to be recruited in order to draw conclusions from the data.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
The aims of the Genomics England CLL pilot
